What is Accuitis?
Accuitis is a biotechnology enterprise dedicated to the development of novel small molecule therapies designed to protect and restore healthy cellular function. The company's primary focus lies in mitigating the progression of neurodegenerative conditions, specifically Alzheimer's and Parkinson's disease. By targeting the restoration of mitochondrial sirt3 expression, Accuitis addresses the underlying mechanisms of age-related cellular decline. This scientific focus places the company within a high-growth niche of the pharmaceutical industry, where the demand for disease-modifying treatments continues to outpace current therapeutic offerings. Their commitment to innovative molecular research positions them as a key contributor to the future of metabolic and neurological medicine.
How much funding has Accuitis raised?
Accuitis has raised a total of $2.8M across 2 funding rounds:
Private Equity
$1.8M
Private Equity
$1M
Private Equity (2015): $1.8M, investors not publicly disclosed
Private Equity (2015): $1M led by The Georgia Research Alliance and Bio/Med Investor Network
Key Investors in Accuitis
The Georgia Research Alliance
The Georgia Research Alliance is a non-profit organization that fosters economic development by investing in university research, recruiting top-tier scientific talent, and supporting the growth of technology-driven startups.
Bio/Med Investor Network
The Bio/Med Investor Network is a group of accredited angel investors specifically focused on providing capital and strategic guidance to early-stage bioscience and healthcare ventures.
Undisclosed Investor
An undisclosed institutional partner providing private equity support to facilitate the early-stage growth and operational scaling of the company.
What's next for Accuitis?
With the recent infusion of capital, Accuitis is poised to transition its lead compound, AN-018, into more advanced stages of development. The strategic roadmap likely involves expanding preclinical research to solidify the efficacy and safety profiles required for human clinical trials. Furthermore, the company is expected to leverage its current partnerships to enhance its intellectual property portfolio and potentially explore collaborative opportunities with larger pharmaceutical entities. As the firm continues to refine its therapeutic platform, the focus will remain on achieving key milestones in mitochondrial health, which could serve as a catalyst for future funding rounds or potential acquisition interest from major industry incumbents.
See full Accuitis company page
